Skip to search formSkip to main contentSkip to account menu

sunitinib

Known as: 1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-, sunitinib [Chemical/Ingredient], 5-(5-fluoro-2-oxo-1,2-dihydroindolylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide 
An indolinone derivative and tyrosine kinase inhibitor with potential antineoplastic activity. Sunitinib blocks the tyrosine kinase activities of… 
National Institutes of Health

Related topics

Related topics

23 relations

Broader (4)

Angiogenesis InhibitorsAntineoplastic AgentsIndolesPyrroles
FLT1 protein, humanFLT3 protein, humanInhibition of Cell ProliferationMast/Stem Cell Growth Factor Receptor Kit, human

Narrower (3)

SU 11248Sutentsunitinib malate

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2012
Review
2012
Sequential therapy with targeted agents in patients with advanced renal cell carcinoma: optimizing patient benefit.
Highly Cited
2012
Highly Cited
2012
Efficacy and safety of everolimus in elderly patients with metastatic renal cell carcinoma: an exploratory analysis of the outcomes of elderly patients in the RECORD-1 Trial.
Review
2011
Review
2011
An algorithm for the management of hypertension in the setting of vascular endothelial growth factor signaling inhibition.
2011
2011
A distinct pediatric-type gastrointestinal stromal tumor in adults: potential role of succinate dehydrogenase subunit A mutations.
Highly Cited
2010
Highly Cited
2010
Pretreatment assessment of tumor enhancement on contrast‐enhanced computed tomography as a potential predictor of treatment outcome in metastatic renal cell carcinoma patients receiving…
Tumor vascularity is a potential predictor of treatment outcomes in metastatic renal cell carcinoma (mRCC), and contrast… 
Review
2010
Review
2010
Targeting mTOR in cancer: renal cell is just a beginning
The mammalian target of rapamycin (mTOR) is a key regulator of cell growth and proliferation. The mTOR pathway integrates signals… 
Review
2010
Review
2010
Novel anticancer agents in clinical trials for well-differentiated neuroendocrine tumors.
2008
2008
Activity of cediranib (AZD2171) in patients (pts) with previously untreated metastatic renal cell cancer (RCC). A phase II trial of the PMH Consortium
5047 Background: Cediranib (AZD2171) is an oral highly potent, selective pan-VEGFR tyrosine kinase inhibitor expected to show… 
Review
2007
Review
2007
Angiogenesis as targeted breast cancer therapy.
Highly Cited
2007
Highly Cited
2007
Exposure-response of sunitinib in metastatic renal cell carcinoma (mRCC): A population pharmacokinetic/pharmacodynamic (PKPD) approach
5027 Background: Sunitinib malate (SU) is an oral, multitargeted tyrosine kinase inhibitor of VEGFRs and PDGFRs, and has shown… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)